Johnson & Johnson's Q3 2010 earnings show continued pressure from the economic slowdown, particularly in the consumer healthcare segment due to recalls and lower volumes.  While pharmaceuticals performed better than expected, the company's guidance for 2010 reflects a cautious outlook on global healthcare spending trends, suggesting potential headwinds in the short term stemming from pricing pressures and volume concerns, although management maintains a commitment to invest in innovative products and acquisitions.  
1
